ReviewCurrent oncology reports2021
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Review in Current oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 226 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
226 citing papers in PubMed, 8 syntheses or guidelines pooled it, 365 citations in OpenAlex.
- Diagnostic performance of artificial intelligence versus conventional imaging for differentiating G2/G3 from G1 pancreatic neuroendocrine tumors: a systematic review and meta-analysis.BMC medical imaging · 2026Pooled it
- Comparison of endoscopic mucosal resection combined with band ligation versus endoscopic submucosal dissection for small rectal neuroendocrine tumors (≤ 10 mm): a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.Endocrine-related cancer · 2026Guideline
- New sights of spleen-preserving versus splenectomy in distal pancreatectomy for pancreatic neuroendocrine tumors: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Pooled it
- Impact of Sex and Deprivation on Neuroendocrine Tumour Survival: Challenges of Heterogeneous Data.Neuroendocrinology · 2025Pooled it
- The therapeutic efficacy ofFrontiers in oncology · 2025Pooled it
- Global research trends in gastroenteropancreatic neuroendocrine tumors: a bibliometric analysis from 2000 to 2023.Frontiers in oncology · 2025Pooled it
- Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [European journal of nuclear medicine and molecular imaging · 2025Trial
- Trial
- A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.JCO oncology practice · 2022Trial
- Ablative magnetic resonance-guided radiation for gastrointestinal neuroendocrine tumors: assessing local control and toxicity.Clinical and translational radiation oncology · 2027Article
- The Use and Utility of Preoperative Somatostatin Receptor-Based Imaging in Gastroenteropancreatic Neuroendocrine Tumors.Annals of surgical oncology · 2026Article
- Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Efficacy and safety of peptide receptor radionuclide therapy in advanced foregut and hindgut neuroendocrine tumors: a real-world experience from a single institution.Annals of nuclear medicine · 2026Article
- Enucleation vs Pancreatoduodenectomy for Benign and Low-Grade Pancreatic Head Tumors.JAMA surgery · 2026Article
- Article
- Article
- NETest2.0Cancers · 2026Article
- FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications.Endocrine-related cancer · 2026Review
166 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThe purpose of our review is to explore global epidemiologic trends of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Specifically, we sought to examine whether there are differences in incidence, prevalence, distribution (by primary tumor site, tumor grade, tumor stage at presentation), and overall survival of GEP NETs between different regions of the world. RECENT
findingsGEP NET incidence rates are rising steadily in North America, Asia, and Europe, though this rise appears to be most profound in North America. The distribution of GEP NETs differs regionally as in North America small intestinal and rectal NETs are most prevalent, in Asia rectal and pancreatic NETs are most prevalent, and in Europe small intestinal and pancreatic NETs are most prevalent. Overall survival for patients with GEP NETs appears to be improving with time. Some of the global increase in GEP NET incidence can be explained by increased health care utilization. This factor alone, however, does not explain the rise completely. Population-based studies utilizing uniform data collection instruments and a standard pathologic grading system are needed to identify other factors which may be contributing to this phenomenon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.